17653-95-1

Basic information

• Product Name: 2-(3-methoxyphenyl)-2-methylpropan-1-ol
• CAS NO: 17653-95-1
• Molecular Formula: C₁₁H₁₆O₂
• Molecular Weight: 180.2435
• Mol File: 17653-95-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 272.7°C at 760 mmHg
• Flash Point: 108.4°C
• Density: 1.014g/cm³
• Vapor Pressure: 0.00292mmHg at 25°C
• Refractive Index: 1.506
• CAS DataBase Reference: 2-(3-methoxyphenyl)-2-methylpropan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-methoxyphenyl)-2-methylpropan-1-ol(17653-95-1)
• EPA Substance Registry System: 2-(3-methoxyphenyl)-2-methylpropan-1-ol(17653-95-1)

Safety Data

• Hazardous Substances Data: 17653-95-1(Hazardous Substances Data)

Usage

Description

2-(3-methoxyphenyl)-2-methylpropan-1-ol, also known as guaifenesin, is a medication primarily used as an expectorant to alleviate coughs and chest congestion. It functions by thinning and loosening mucus in the airways, facilitating easier expectoration. Guaifenesin is a central component in numerous over-the-counter cough and cold remedies and is generally well-tolerated with minimal side effects. It is derived from the natural compound guaiacol and is frequently combined with other medications, such as cough suppressants and decongestants, to provide relief from cold and respiratory symptoms.

Uses

Used in Pharmaceutical Industry:
2-(3-methoxyphenyl)-2-methylpropan-1-ol is used as an expectorant in the pharmaceutical industry for its ability to thin and loosen mucus in the airways, making it easier for individuals to cough up phlegm and relieve coughs and chest congestion.
Used in Over-the-Counter Medications:
2-(3-methoxyphenyl)-2-methylpropan-1-ol is used as an active ingredient in over-the-counter cough and cold medications for its effectiveness in treating respiratory symptoms associated with colds and other respiratory conditions.
Used in Combination Therapies:
2-(3-methoxyphenyl)-2-methylpropan-1-ol is used in combination with other medications, such as cough suppressants and decongestants, to provide comprehensive relief from cold and respiratory symptoms, enhancing the overall therapeutic effect for patients.

Upstream product

• 17653-93-9 2-(3'-Methoxyphenyl)-2-methylpropionitrile 
• 728912-67-2 ethyl 2-(3-methoxyphenyl)-2-methyl-propanoate 
• 17653-94-0 α-methyl-α-(3-methoxyphenyl)proprionic acid 
• 32454-33-4 methyl 2-(3-methoxyphenyl)-2-methylpropanoate 

Downstream Products

• 72925-77-0 m-Methoxyneophyl methanesulfonate 
• 1415599-04-0 1-methoxy-3-[2-(methoxymethoxy)-1,1-dimethyl-ethyl]benzene 
• 6380-20-7 3-isopropylanisole 
• 74773-09-4 5-{4-[2-(3-Methoxy-phenyl)-2-methyl-propoxy]-benzyl}-thiazolidine-2,4-dione 
• 85003-08-3 2-Chloro-3-{4-[2-(3-methoxy-phenyl)-2-methyl-propoxy]-phenyl}-propionic acid methyl ester 
• 17653-96-2 3-(m-methoxyphenyl)-3-methylbutyronitrile 
• 85002-51-3 4-<2-(3-methoxyphenyl)-2-methylpropoxy>nitrobenzene 
• 32454-15-2 2-methyl-2-(m-methoxyphenyl)-1-propanal 
• 109397-19-5 2-(3-methoxy-phenyl)-2-methyl-1-(toluene-4-sulfonyloxy)-propane 

Relevant articles and documents

HYDANTOIN DERIVATIVES AS KV3 INHIBITORS

The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors

A class of less toxic retinoids, called heteroarotinoids, was evaluated for their molecular mechanism of growth inhibition of two head and neck squamous cell carcinoma (HNSCC) cell lines SCC-2 and SCC-38. A series of 14 heteroarotinoids were screened for growth inhibition activity in vitro. The two most active compounds, one that contained an oxygen heteroatom (6) and the other a sulfur heteroatom (16), were evaluated in a xenograph model of tumor establishment in nude mice. Five days after subcutaneous injection of 107 SCC-38 cells, groups of 5 nu/nu mice were gavaged daily (5 days/week for 4 weeks) with 20 mg/kg/day of all-trans-retinoic acid (t-RA, 1), 10 mg/kg/day of 6, 10 mg/kg/day of 16, or sesame oil. After a few days, the dose of t-RA (1) was decreased to 10 mg/kg/day to alleviate the side effects of eczema and bone fracture. No significant toxic effects were observed in the heteroarotinoid groups. All three retinoids caused a statistically significant reduction in tumor size as determined by the student t-test (P 0.05). Complete tumor regression was noted in 3 of 5 mice treated with t-RA (1), 4 of 5 mice treated with 16, 1 of 5 mice treated with 6, and 1 of 5 mice treated with sesame oil. Reverse transcriptase polymerase chain reaction (RT- PCR) was used to determine that the expression levels of RARα, RXRα, and RXRβ were similar in the two cell lines, while RARβ expression was higher in SCC-2 over SCC-38, and RARγ expression was higher in SCC-38 over SCC-2. Receptor cotransfection assays in CV-1 cells demonstrated that 16 was a potent activator of both RAR and RXR receptors, while 6 was selective for the RXR receptors. Transient cotransfection assays in CV-1 cells using an AP-1 responsive reporter plasmid demonstrated that t-RA (1), 6, and 16 each inhibited AP-1-driven transcription in this cell line. In conclusion, the growth inhibition activity of the RXR-selective 6 and the more potent growth inhibition activity of the RAR/pan-agonist 16 implicate both RARs and RXRs in the molecular mechanism of retinoid growth inhibition. Moreover, the chemoprevention activity and the lack of toxicity of heteroarotinoids demonstrate their clinical potential in head and neck cancer chemoprevention.